- Current report filing (8-K)
November 25 2009 - 12:21PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported event): November 24, 2009
GEOPHARMA, INC.
(Exact name of registrant as specified in charter)
|
|
|
|
|
|
|
Florida
|
|
001-16185
|
|
59-2600232
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
6950 Bryan Dairy Road, Largo, Florida
|
|
33777
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including area code: (727) 544-8866
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 2.02 Results of Operations
On November 24, 2009, GeoPharma, Inc. issued a press release announcing its results of operations as of and for the three and six months ended September 30, 2009, a copy of which is attached as Exhibit 99.1 hereto.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
|
ITEM 9.01.
|
. Financial Statements and Exhibits.
|
(c) Exhibits. The following documents are filed as exhibits to this report:
99.1 Press release issued November 24, 200
9
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorize
|
|
|
|
|
|
|
GEOPHARMA, INC.
|
|
|
|
|
Date: November 24, 2009
|
|
/s/ Mihir K. Taneja
|
|
|
|
Mihir K. Taneja,
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
/s/ Carol Dore-Falcone
|
|
|
|
Carol Dore-Falcone,
|
|
|
|
Senior Vice President and Chief Financial Officer
|
3
Geopharma (NASDAQ:GORX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Geopharma (NASDAQ:GORX)
Historical Stock Chart
From Apr 2023 to Apr 2024
